ESSA Pharma Inc. Held Special Meeting of Securityholders Regarding Acquisition by XenoTherapeutics
I'm PortAI, I can summarize articles.
ESSA Pharma Inc. held a special meeting on October 6, 2025, where securityholders approved the acquisition by XenoTherapeutics Inc. They also approved voluntary liquidation if the acquisition is terminated, appointing PricewaterhouseCoopers LLP as liquidator. The acquisition is pending court approval, with final approval expected on October 7, 2025, and completion anticipated around October 9, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments